ArticleAnnals of surgical oncology2026
Preoperative Nutritional Risk Defines Treatment Tolerance and Guides Adjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalnutrition is a critical determinant of treatment tolerance in esophageal squamous cell carcinoma (ESCC). However, its utility in guiding dynamic perioperative decision-making and adjuvant immunotherapy selection remains undefined.
methodsThis study evaluated 498 locally advanced ESCC patients receiving neoadjuvant chemoimmunotherapy and planned esophagectomy. A classification and regression tree (CART) model stratified patients by baseline PG-SGA score. The primary endpoint was treatment tolerance as defined by a composite Neoadjuvant Therapy Tolerance Grade (NAT-TG) that integrated therapy completion and surgical feasibility. The secondary endpoints included postoperative morbidity and survival outcomes. Additionally, dynamic preoperative nutritional trajectories were longitudinally tracked.
resultsThe CART model identified three distinct nutritional risk strata. Increasing nutritional risk was strongly associated with impaired treatment tolerance, reflected by reduced surgical completion (97.1% vs 93.3% vs 76.7%; P < 0.001) and higher-grade (≥3) toxicities. High-risk patients experienced significantly more severe postoperative complications (38.2% vs 18.0%; P < 0.001). Longitudinal monitoring showed that a persistent-severe dynamic nutritional trajectory independently predicted major postoperative complications (odds ratio, 3.21; P < 0.001). At a median follow-up period of 41 months, baseline high nutritional risk independently predicted inferior overall survival (hazard ratio, 2.03; P < 0.001). Notably, within the cohort that underwent resection, adjuvant immunotherapy significantly improved 3-year overall survival for high-risk patients, from 41.7% to 65.8% (P = 0.043), whereas no such benefit was observed in lower-risk groups.
conclusionsIntegrating baseline nutritional triage with dynamic longitudinal monitoring effectively predicts treatment tolerance and prognosis in ESCC. This framework identifies a high-risk subset that derives substantial survival benefit from adjuvant immunotherapy consolidation.
Indexed as
Identifiers
42418078What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.